PD-L1 lineage-specific quantification in malignant pleural effusions of lung adenocarcinoma by flow cytometry

PD-1/PD-L1 blockade is now a well-established therapeutic strategy in non-small cell lung cancer (NSCLC). Pembrolizumab monotherapy is approved by Food and Drug Administration (FDA), European Medicines Agency (EMA), and Japanese Ministry of Health, Labour and Welfare (MHLW) for first-line treatment in metastatic NSCLC with high PD-L1 expression and lack of a targetable driver mutation [1]. The pembrolizumab companion PD-L1 immunohistochemistry (IHC) uses the antibody 22C3 clone. PD-L1 expression detected as tumor cell membrane staining is semi-quantitatively assessed microscopically.

Source: Lung Cancer - July 30, 2020 Category: Cancer & Oncology Authors: Ju-Yoon Yoon, Rakesh Nayyar, Graeme Quest, Dana Pabedinskas, Prodipto Pal, Ming-Sound Tsao, Joerg Schwock, Hyang-Mi Ko Source Type: research